MTNB - Matinas BioPharma Holdings, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
0.7039
+0.0067 (+0.96%)
As of 10:15AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.6972
Open0.7091
Bid0.7040 x 1200
Ask0.7099 x 1000
Day's Range0.7000 - 0.7128
52 Week Range0.5010 - 1.5000
Volume42,692
Avg. Volume497,378
Market Cap114.694M
Beta (3Y Monthly)3.11
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire

    Matinas BioPharma Initiates EnACT Study of MAT2203 (Oral Amphotericin B) for the Treatment of Fungal Cryptococcal Meningitis

    Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical stage biopharmaceutical company, today announced that it has initiated its Phase 2 EnACT clinical study, which will explore the use of MAT2203 for both induction and maintenance therapy in HIV-patients with cryptococcal meningitis, a life-threatening fungal infection most commonly observed in immunocompromised individuals. “We are extremely pleased to advance clinical development of MAT2203 for the treatment of cryptococcal meningitis,” commented Theresa Matkovits, Ph.D., Chief Development Officer of Matinas. “Antifungal resistance poses a major threat to the lives of vulnerable immunocompromised patients, and MAT2203 could provide an invaluable oral and safe treatment for severe fungal infections in these patients.

  • GlobeNewswire

    Matinas BioPharma Receives Orphan Drug Designation From U.S. FDA for MAT2203 for the Treatment of Cryptococcosis

    Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to MAT2203, Matinas’ proprietary oral amphotericin B product, for the treatment of cryptococcosis, a life-threatening fungal infection most commonly observed in immunocompromised individuals. MAT2203 is Matinas’ orally-administered formulation of the broad-spectrum fungicidal medication amphotericin B, which is currently in Phase 2 clinical development.

  • GlobeNewswire

    Matinas BioPharma to Present at the 2019 Cantor Global Healthcare Conference

    Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical stage biopharmaceutical company, today announced that Jerome D. Jabbour, Chief Executive Officer, will present a company overview, as well as host investor meetings, at the 2019 Cantor Global Healthcare Conference. Investors interested in arranging a meeting with the Company's management during this conference should contact the conference coordinator. A live audio webcast of the presentation will be available on the Events page of the Investors section of the Company’s website (www.matinasbiopharma.com).

  • GlobeNewswire

    Matinas BioPharma Announces Pre-Screening of Patients to Determine Eligibility for Phase 2 ENHANCE-IT Study Against Vascepa®

    Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical stage biopharmaceutical company, today announced that it has commenced pre-screening patients to determine eligibility for ENHANCE-IT, its Phase 2 head-to-head pharmacodynamic (PD) study of MAT9001 against Vascepa in patients with elevated triglycerides (150-499 mg/dL). “Our second head-to-head trial against Vascepa is an important milestone for our Company, and pre-screening patients for eligibility will facilitate rapid enrollment in the first quarter of 2020,” commented Jerome D. Jabbour, Chief Executive Officer of Matinas. The “ENHANCE-IT trial (Pharmacodynamic effects of a free fatty acid formulation of omega-3 pentaenoic acids to enhance efficacy in adults with elevated triglycerides) will be led by Kevin C. Maki, Ph.D., President and Chief Scientist of Midwest Biomedical Research, and is expected to involve approximately six sites in the United States.

  • GlobeNewswire

    Matinas BioPharma to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical stage biopharmaceutical company, today announced that Jerome D. Jabbour, Chief Executive Officer, will present a company overview, as well as host investor meetings, at the H.C. Wainwright 21st Annual Global Investment Conference. Investors interested in arranging a meeting with the Company's management during this conference should contact the conference coordinator. A live audio webcast of the presentation will be available on the Events page of the Investors section of the Company’s website (www.matinasbiopharma.com).

  • GlobeNewswire

    Matinas BioPharma Reports Second Quarter 2019 Financial Results and Provides Corporate Update

    – MAT9001 program progressing ahead of schedule – – Additional head to head data vs. Vascepa® expected in 2020 – – NIH-funded Phase 1/2 EnACT trial of MAT2203.

  • ACCESSWIRE

    Matinas Biopharma Holdings, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 13, 2019 / Matinas Biopharma Holdings, Inc. (NYSEMKT: MTNB ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on August 13, ...

  • GlobeNewswire

    Matinas BioPharma to Webcast Conference Call Discussing Second Quarter 2019 Operational and Financial Results on August 13, 2019

    Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live webcast on Tuesday, August 13, 2019 at 8:00 a.m. ET to discuss operational and financial results for the quarter ended June 30, 2019, as well as provide a corporate update. Matinas BioPharma is a clinical-stage biopharmaceutical company focused on development of its lead product candidate, MAT9001, for the treatment of cardiovascular and metabolic conditions. The Company is actively pursuing the development of MAT9001 with the support of a world-class team of clinical key opinion leaders and regulatory consultants.

  • GlobeNewswire

    Matinas BioPharma Receives Qualified Infectious Disease Product (QIDP) and Fast Track Designations From U.S. FDA for MAT2203 for the Treatment of Cryptococcal Meningitis

    Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has designated MAT2203, Matinas’ proprietary oral amphotericin B product, as a Qualified Infectious Disease Product (QIDP) with Fast Track status for the treatment of cryptococcal meningitis. As previously reported, the FDA has designated MAT2203 as a QIDP with Fast Track status for three other indications, specifically, the prevention of invasive fungal infections due to immunosuppressive therapy, treatment of invasive candidiasis, and treatment of invasive aspergillus.

  • GlobeNewswire

    Matinas BioPharma to Present at the 9th Annual LD Micro Invitational

    Matinas BioPharma is a clinical-stage biopharmaceutical company focused on creating value through the streamlined development of MAT9001 for the treatment of cardiovascular and metabolic conditions and the application of its lipid nano-crystal (“LNC”) platform technology to solve complex challenges relating to the safe and effective delivery of small molecules, gene therapies, proteins, peptides and vaccines. The Company is actively pursuing the development of MAT9001 with the support of a world-class team of clinical key opinion leaders and regulatory consultants. MAT9001 is a prescription-only omega-3 fatty acid-based composition, comprised primarily of EPA and DPA, under development for hypertriglyceridemia, which has shown superiority versus Vascepa® (icosapent ethyl) in reducing serum triglycerides, Total- and Non-HDL-Cholesterol, apolipoprotein CIII and PCSK9 levels.

  • GlobeNewswire

    Matinas BioPharma Announces Publication of MAT2203 Preclinical Cryptococcal Meningitis Data in the American Society for Microbiology Journal, mBio

    – Efficacy of oral delivery of amphotericin B (MAT2203) demonstrated comparable efficacy to IV amphotericin, with similar survival of animals and reduction in fungal burden – –.

  • GlobeNewswire

    Matinas BioPharma Announces Abstract Accepted for Presentation at ASM Microbe 2019

    Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that its abstract of preclinical data of MAT2501, an orally administered, lipid nano-crystal (“LNC”) formulation of the broad spectrum aminoglycoside antibiotic agent amikacin, has been selected for two presentations at the ASM Microbe 2019 scientific meeting being held June 20–24 in San Francisco, CA.

  • GlobeNewswire

    Matinas BioPharma Announces a Research Collaboration with ViiV Healthcare to Evaluate Formulation of Antiviral Drug Candidates

    Formulations of select antivirals will be developed using Matinas’ LNC platform delivery technology, which enables the development of a wide range of difficult-to-deliver molecules. Promising formulations will be tested in in vivo preclinical studies to identify a lead LNC-antiviral formulation to take forward in development.

  • GlobeNewswire

    Matinas BioPharma Provides Corporate Update and Reports First Quarter 2019 Financial Results

    BEDMINSTER, N.J., May 14, 2019 -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced its financial results for the.

  • GlobeNewswire

    Matinas BioPharma to Host Conference Call and Webcast to Discuss First Quarter 2019 Operational and Financial Results on May 14, 2019

    Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Tuesday, May 14, 2019 at 8:30 a.m. ET to discuss operational and financial results for the quarter ended March 31, 2019 as well as provide a corporate update. Matinas BioPharma is a clinical-stage biopharmaceutical company focused on creating value through the streamlined development of its lead product candidate, MAT9001, for the treatment of cardiovascular and metabolic conditions and the application of its lipid nano-crystal (“LNC”) platform technology to solve complex challenges relating to the safe and effective delivery of small molecules, gene therapies, proteins, peptides and vaccines.

  • GlobeNewswire

    Matinas BioPharma to Ring NYSE Opening Bell® on May 6, 2019

    BEDMINSTER, N.J., May 02, 2019 -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that it has been invited to.

  • GlobeNewswire

    Matinas BioPharma Selected to Present at the BioNJ Ninth Annual BioPartnering Conference

    Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that Theresa Matkovits, Ph.D., Chief Development Officer of the Company, was selected to present a corporate overview and host one-on-one meetings with leading industry executives at BioNJ’s Ninth Annual BioPartnering Conference on Wednesday, May 8, 2019 during the afternoon session being held 2:00 PM – 3:00 PM ET. As part of her presentation, Dr. Matkovits will provide a corporate update and will discuss the Company’s differentiated LNC drug delivery platform. Matinas’ LNC platform technology offers an intracellular drug delivery solution with potential advantages for a range of therapeutics, including small molecules, nucleic acid polymers, proteins, peptides, vaccines, as well as the targeted delivery of gene editing technologies.  Dr. Matkovits will also provide an overview of the Company’s lead anti-infective pipeline candidate, MAT2203.

  • GlobeNewswire

    Matinas BioPharma Reports 2018 Financial Results and Provides Corporate Update

    –  Key focus on advancing the development of MAT9001, a potential best-in-class cardiovascular therapy in what is projected to be a new, multi-billion dollar prescription-only.

  • GlobeNewswire

    Matinas BioPharma to Announce Full-Year 2018 Operational and Financial Results on April 2, 2019

    The call will be led by Jerome D. Jabbour, Chief Executive Officer of Matinas. Forward Looking Statements: This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including those relating to the Company's anticipated capital and liquidity needs, strategic focus and the future development of its product candidates, including MAT9001 and MAT2203, the anticipated timing of regulatory submissions, the anticipated timing of clinical studies, the anticipated timing of regulatory interactions, the Company’s ability to identify and pursue development and partnership opportunities for its products or platform delivery technology on favorable terms, if at all, and the ability to obtain required regulatory approval and other statements that are predictive in nature, that depend upon or refer to future events or conditions.

  • Business Wire

    Matinas BioPharma to Present at the 31st Annual ROTH Conference

    Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that Jerome D. Jabbour, Chief Executive Officer, will present at the 31st Annual ROTH Conference on Tuesday, March 19 at 2:30 PM PT in Dana Point, CA. As part of his presentation, Mr. Jabbour will provide a corporate update and will discuss MAT9001, the Company’s proprietary prescription-only omega-3 fatty acid-based composition. Matinas is developing MAT9001 for therapeutic applications in the cardiovascular and metabolic fields with the support of a world-class team of clinical key opinion leaders and regulatory consultants.

  • Business Wire

    Matinas BioPharma Announces Pricing of Public Offering of Common Stock

    Matinas BioPharma Holdings, Inc. (“Matinas BioPharma” or the “Company”) -- (NYSE AMER:MTNB), a clinical-stage biopharmaceutical company, today announced the pricing of its underwritten registered public offering of 27,272,727 shares of its common stock, offered at a price to the public of $1.10 per share for expected gross proceeds of $30.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses. In addition, Matinas BioPharma has granted the underwriters a 30-day option to purchase up to an additional 4,090,909 shares of its common stock on the same terms and conditions. All of the shares in the offering are being sold by Matinas BioPharma.

  • Business Wire

    Matinas BioPharma Announces Proposed Public Offering of Common Stock

    Matinas BioPharma Holdings, Inc. (“Matinas BioPharma” or the “Company”) -- (NYSE AMER:MTNB), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of its common stock. All of the shares to be sold in the offering are to be sold by Matinas BioPharma. In connection with the offering, Matinas BioPharma intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering.

  • GlobeNewswire

    Prominent Cardiovascular Expert, James J. Ferguson, M.D., FACC, FAHA Joins Matinas BioPharma as Chief Medical Officer

    Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that it has appointed a prominent cardiovascular medical and clinical development expert, James (“Terry”) J. Ferguson, M.D., FACC, FAHA, as its Chief Medical Officer.

  • ACCESSWIRE

    Biotech Breaking Out

    HENDERSON, NV / ACCESSWIRE / January 16, 2019 / Since hitting its lows on Dec. 26, biotech has soared more than 20 percent as of Friday, and was posting its best start to a year since 2012. Here are a ...

  • GlobeNewswire

    Matinas BioPharma Announces a Research Evaluation with Top Global Pharma Company Based on Its Proprietary Drug Delivery Platform

    Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical stage biopharmaceutical company, today announced they have signed an agreement with an undisclosed top global pharmaceutical company aimed to evaluate synergistic effects of Matinas’ lipid-nano-crystal (“LNC”) platform delivery technology with their partner’s nucleic acid polymer technology. Formulations will be developed using Matinas’ LNC delivery technology which enables the development of a wide range of difficult-to-deliver molecules. For competitive reasons, the agreement stipulates certain confidential provisions, including the pharmaceutical company’s identity, the therapeutic molecule(s), the intended targets and the financial terms of the agreement.